Review article on “Amphiregulin in Fibrotic Diseases and Cancer” published in IJMS

Execution of an Exclusive License Agreement between siRNAgen and Cenos Therapeutics for SAMiRNA Glut CNS therapeutics

SRN001, Preclinical toxicity study in monkeys published in Toxicol. Res.

CDMO business launch

SRN001, Receive the CSR of Australian Phase 1a clinical trial

SRN001, Registration of Japanese patent for obesity treatment composition

SRN001, Registration of US patent for SRN001 compound

SRN001, Initiation of Phase 1a clinical trial for idiopathic pulmonary fibrosis (IPF)

PCT patent application filed for the SAMiRNA-Glut CNS therapy platform

Execution of an Exclusive License Agreement between Bioneer and siRNAgen for SAMiRNA technology

SRN001, Registration of Japanese patent for fibrosis treatment candidate substance

2022 Seoul Innovation QuickFire Challenge Award

SRN001, Total-body-irradiation-induced fibrosis efficacy published in Radiat. Res.

SRN001, Preclinical toxicity study in Mice published in Int. J. Toxicol.

Korean registration of the siRNAgen Therapeutics trademark

SRN001, Preclinical genotoxicity study published in Drug Chem Toxicol.

SRN001, Preclinical Safety pharmacology study published in Toxicol Rep.

SRN001, Renal fibrosis efficacy published in Sci Rep.

siRNAgen Therapeutics spun off from BIONEER